Intrinsic Value of S&P & Nasdaq Contact Us

AVROBIO, Inc. AVRO NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
31/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

AVROBIO, Inc. (AVRO) reported total assets of $261.04M and total liabilities of $9.71M for quarter ending 2025-12-31, resulting in total equity of $251.33M.

The company held $253.8M in cash and short-term investments. Total debt stood at $1.28M, with net debt of $-252.52M. The Debt-to-Equity (D/E) ratio was 0.01 (conservative).

Current ratio is 26.63, indicating strong short-term liquidity. Interest coverage is -188.7x (weak).

Criteria supported by this page:

  • HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
  • MOAT (28/100) — Total assets $261.04M and equity $251.33M support the company's competitive scale

Overall SharesGrow Score: 29/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score
31/100
SG Score
View full scorecard →
VALUE
N/A
No coverage
FUTURE
20/100
Analyst consensus
→ Forecast
PAST
25/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
28/100
Proven by this page
GROWTH
15/100
→ Income
INCOME
N/A
No coverage
AVROBIO, Inc. Balance Sheet History
Metric Q4 FY2025 Q3 FY2025 Q2 FY2025 Q1 FY2025
Total Assets $261.04M$277M$295.31M$314.83M
Total Liabilities $9.71M$9.47M$11.55M$13.79M
Total Debt $1.28M$1.24M$1.94M$2.63M
Cash & Investments $253.8M$268.44M$287.38M$306.25M
Total Stockholders Equity $251.33M$267.53M$283.77M$301.04M
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message